CN105177025A - Type 18 recombinant human papilloma virus virus-like particle and preparation method thereof - Google Patents

Abstract

The invention relates to a type 18 recombinant human papilloma virus virus-like particle and a preparation method thereof. According to the specific technical key point, the invention aims to provide a new coded and recombinant HPV118 L1 protein's polynucleotide gene segment, a carrier containing the gene segment, a host cell containing the carrier, HPV118 L1 fusion protein translated and expressed by the gene segment, a pentamer and VLP formed by the pentamer. The invention also discloses application of the pentamer, the VLP protein and vaccine compositions formed thereby in preparation of drugs preventing HPV118 infection.

Description

18 type recombinant human papilloma virus virus-like particles and preparation method thereof

Technical field

The present invention relates to human papillomavirus virus-like particleand preparation method thereof.More specifically, the present invention relates to a kind of pentamer and virus-like particle (Virus-likeParticle, VLP) and preparation method thereof of human mammilla tumor virus L 1 albumen of restructuring, and containing being somebody's turn to do virus-like particlethe application of vaccine composition in prevention of human papillomavirus infection.

Background technology

Human papillomavirus (HumanPapillomavirus is called for short HPV), mainly through human body close contact, as the virus spread through sex intercourse, can cause the multiple proliferative epithelial lesion of the mankind, comprise papilloma (wart) and tumor-like lesion.Specifically, the disease that HPV brings out mainly comprises 3 large classes, the 1st class: the malignant changes such as the cancer of uterine neck, vagina, female vulva, penis and anus and the tumor of head and neck of some type.The cervical cancer patient of 100% is all that HPV infects and causes, the anus cancer of 90%, and the vulva of 40%, vagina and penis, the oropharynx of 12% and the mouth cancers of 3% infect owing to HPV.2nd class: benign lesion, as the Genital warts such as verruca plana, pointed condyloma, is a kind of sexually transmitted disease (STD), very common in the crowd that sexual behaviour is active.Although Genital warts can not cause serious consequence as cancer; but the clinical symptom that pathology can cause patient comparatively painful is usually as cusalgia, hemorrhage and pain; produce embarrassment, anxiety simultaneously and to feel oneself inferior etc. negative and psychoreaction, and the process of repeatedly treating wastes a large amount of medical resources.Worldwide estimate that the Genital warts caused by non-carcinogenic HPV (mainly 6 and 11 types) has 3,000 ten thousand, wherein 20 ~ 50% pathology in also include the polyinfection of high-risk HPV.3rd class: HPV infects can also cause recurrent respiratory papilloma (RRP), this be a kind of rare, there is potential fatefulue disease, mainly occur in adolescence, sometimes, a large amount of papillomas can cause has difficulty in breathing and causes less age death of child.So prevention or treatment HPV infect very great to human health meaning.

HPV is the double-stranded DNA virus without cyst membrane, primarily of virus coat and genomic dna composition (Bernard, Burketal.2011).HPV virus coat is by 360 L1 protein (forming 72 pentamers) and the icosahedral structure of virus that forms of 72 L2 protein at the most, diameter 55 ~ 60nm (HowleyandLowy2007).Virus capsid protein matter has self-assembly characteristic, L1 protein separately or form viral all particle (Virus-likeParticle with L2 protein co-assemble in vitro, VLP) (Chen, Garceaetal.2000, Finnen, Ericksonetal.2003, Buck, Chengetal.2008, WangandRoden2013).

Because HPV can not cell cultures in vitro, the specific antigens of this virus be obtained, recombinant vaccine can only be prepared by the method for recombinant DNA technology.The virus-like particle VLPs that restructuring Ll or L1/L2 assembling is formed, virus-free DNA, security is good, have with natural viral Particle Phase like epitope, neutralizing antibody IgG and IgA can be produced after stimulating body, therefore HPVVLPs can be used as preventative vaccine, thus greatly reduces the possibility (HowleyandLowy2007) causing producing related neoplasms because infecting HPV.

The key of HPV vaccine development to prepare high purity, stable HPV antigen in a large number.In HPV vaccine antigen technology of preparing, the expression system of production HPV antigen comparatively conventional at present can be divided into eukaryotic expression system and prokaryotic expression system.Conventional eukaryotic expression system has pox viruses express system, insect baculovirus expression system, yeast expression system.The formation VLP that HPVL1 energy expressed in eukaryotic expression system is spontaneous, often only need carry out simple purifying can obtain VLP.But because the expression amount of eukaryotic expression system is low, toxigenic capacity is high, brings extreme difficulties to large-scale industrial production.Utilize escherichia expression system to express HPVL1 protein in prokaryotic expression system to have been reported.But the HPVL1 protein solubility expressed by intestinal bacteria is low, purification process known at present obtains HPVVLP by the steps such as salt-free precipitation or sex change renaturation final purifying from the numerous and diverse enchylema of kinds of protein mostly.Such as: open by procaryotic cell expression and the polymeric method of preparation HPVL1 in patent CN02129070.9, wherein purifying process comprises by 3.3M Urea treatment and dialysis renaturation process; Also be by urea-denatured process to the purification process of L1-GST fused protein in WO-0204007 patent and carry out dialysis renaturation; Also there is open L1 protein purification method to be comprise phosphoric acid buffer ultrafiltration dialysis and centrifugal in the prior art, make target protein precipitate the step of redissolving again.But in these purge processes, protein losses amount is large, and yield is low, is difficult to apply in scale operation.

In the homogeneity of HPV vaccine antigen protein matter VLP, the grain size dispersity of the HPVL1VLP assembled in prior art has use polyd value to represent, polyd value <15% illustrates that particle has good homogeneity, illustrate between 15% to 30% that particle has larger unhomogeneity, be greater than 30% explanation particle homogeneous completely not.The HPVL1VLP prepared in prior art is much in 15%.Another illustrates that the index of uniform particle diameter is PdI value, and PdI value is size distribution coefficient, is less than 0.05 for highly homogeneous sample; 0.05 ~ 0.1 is as the criterion homogeneous sample, and 0.1 ~ 0.3 is the poor sample of homogeneity, is greater than 0.3 for inhomogenous sample.The PdI disclosing the mixed protein liquid of two type HPVL1VLP in US7205125B2 patent is 0.07.

Therefore, this area still need that cost is low, purity is high, output is high, the novel method of stay-in-grade HPVL1 protein production technology and large-scale industrial production restructuring HPVL1VLP.

Summary of the invention

The object of the invention is the nucleotide sequence of the coding HPV18L1 protein of openly a kind of optimization, comprise the carrier of this nucleotide sequence, comprise the host cell of carrier, and by the HPVL1 protein of this polynucleotide sequence accurate translation, Tag-HPV-L1 recombinant protein, the pentamer formed by this L1 protein and VLP, and the vaccine infected as the prevention HPV that antigen forms by this pentamer and VLP.

first aspect present invention provides a kind of gene through codon optimized HPV18L1, its nucleotides sequence is classified as SEQNO:2.

second aspect present invention provides a kind of expression vector of structure,it comprises the gene through codon optimized HPV18L1 of first aspect present invention.Described carrier is applicable to driving allogeneic dna sequence DNA accurate translation HPVL1 protein in bacterium.In one embodiment, described expression vector preferred pGEX-6p-1, pGEX-4T-2, pMAL or pET28a.

a third aspect of the present invention provides a kind of engineering bacteria cell of structure,this cell comprises the gene of first aspect present invention, or the expression vector of second aspect.Described engineering bacteria host cell is intestinal bacteria, in one embodiment, and the preferred BL21 cell strain of described host cell.

fourth aspect present invention provides a kind of Tag-HPV18L1 fusion rotein,wherein label Tag is 6*His.Tag, GST.Tag, SUMO.Tag, MBP.Tag, 6*His-SUMO.Tag or GST-SUMO.Tag; L1 is that HPV18L1 full length protein and/or C hold brachymemma 5,10,15 or no more than 30 amino acid and/or N to hold brachymemma 2,4,6 or no more than 10 amino acid whose L1 protein.

The nucleotides sequence of coding Tag-HPVL1 fusion rotein GST-HPV18L1 is classified as SEQNO:3, SEQNO:11, the nucleotides sequence of GST-SUMO-HPV18L1 is classified as SEQNO:4, SEQNO:12, nucleotide sequence SEQNO:5, SEQNO:13 of MBP, the nucleotides sequence of 6*His-HPV18L1 is classified as SEQNO:6, and the nucleotides sequence of 6*His-SUMO-HPV18L1 is classified as SEQNO:7.

The aminoacid sequence SEQNO:10 of the aminoacid sequence of coding Tag-HPVL1 fusion rotein GST-HPV18L1 to be the aminoacid sequence of SEQNO:8, GST-SUMO-HPV18L1 be SEQNO:9, MBP.

the pentamer of the HPVL1 that fifth aspect present invention provides Tag-HPVL1 fused protein to obtain after purifying, and the VLP assembled by pentamer.hPV18L1 pentamer albumen median size 10 ~ 15nmPdI<0.1 in a preferred embodiment.Median size 45 ~ the 65nmPdI<0.1 of HPV18L1VLP in a preferred embodiment.

sixth aspect present invention provides a kind of vaccine composition,it comprises the pentamer of HPVL1 of the present invention or the VLP of HPVL1, comprises pharmaceutically useful vehicle and medicinal adjuvant further in described composition.

Absorption preparation will be carried out with aluminum hydroxide adjuvant normal saline solution according to albumen and aluminium content 1:10 ratio respectively containing HPV18L1 pentamer or VLP albumen stoste (preparing gained according to aforesaid method) in one embodiment and can obtain recombinate HPVL1 protein pentamer or VLP vaccine, stand-by 4 DEG C of preservations.

on the other hand, the present invention also provides a kind of method obtaining Tag-HPVL1 fusion rotein, comprises the steps:

A. by replacing the codon of the translation same protein of HPV18L1 gene order with the codon of intestinal bacteria preference, the gene of the codon optimized HPV18L1 of escherichia expression system preference is obtained;

B. the coli expression carrier of HPV18L1 gene is built;

C. the escherichia coli expression engineering strain of Tag-HPV18L1 is built;

D. abduction delivering purifying obtains fusion rotein Tag-HPV18L1.

Above-mentionedly prepare prokaryotic host cell in fusion rotein Tag-HPV18L1 method and be selected from but be not limited to GI698, ER2566, BL21 (DE3), XA90, B834 (DE3), BLR (DE3).

Above-mentionedly prepare expression condition in fusion rotein Tag-HPV18L1 method and be: under 20 ~ 37 DEG C of temperature condition, abduction delivering 3 ~ 20 hours.Preferred under 28 DEG C of temperature condition in a specific embodiment, abduction delivering 16 hours.

the present invention also provides a kind of method obtaining HPV18L1 pentamer, comprises the steps:

A) with affinity chromatography method absorption fusion rotein Tag-HPV18L1;

B) add proteolytic enzyme excision Tag label, obtain HPV18L1 pentamer protein;

C) purifying HPVL1 pentamer protein, obtain purity >98%, the L1 pentamer protein of median size 10 ~ 15nmPdI<0.1.

Be the site-specific proteolytic enzyme of excision Tag label for proteolytic enzyme described in above-mentioned preparation HPV18L1 pentamer method: restructuring HRV 3CP, zymoplasm, SUMO proteolytic enzyme, SENP1 or TEV protease.

In above-mentioned preparation HPV18L1 pentamer method, purification process is selected from but is not limited to ion exchange chromatography, hydrophobic chromatography method, molecular sieve (or claiming gel-filtration or size-exclusion) chromatography; Preferably purifying comprises ion exchange chromatography and molecular sieve chromatography.

In above-mentioned preparation HPV18L1 pentamer method, purification process also comprises use reductive agent, such as, add DTT.

HPV18L1 pentamer albumen median size 10 ~ 15nmPdI<0.1 is obtained after final purifying in above-mentioned preparation HPV18L1 pentamer method.

present invention also offers a kind of method that HPV18L1 pentamer is assembled into VLP, comprise the steps:

The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is mixed with assembling damping fluid, final acquisition pH value is 5.0 ~ 5.9, salt concn is 500 ~ 2000mM, the HPV18L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1, preferred acquisition pH value is 5.7, and salt concn is the HPV18L1VLP protein liquid of 1300mM.

Assembling damping fluid includes but not limited to Tris damping fluid, phosphate buffered saline buffer, acetate buffer solution, HEPES damping fluid, MOPS damping fluid, citrate buffer, histidine buffering liquid, borate buffer etc.

Above-mentioned HPV18L1 pentamer is assembled in the method for VLP can also add protective material in HPV18L1-VLP protein liquid, such as: 0.01 ~ 0.1 Polysorbate 80.

present invention also offers the method-cryogenic freezing process construction from part of another kind of assembling VLP, comprise the steps:

HPVL1 pentamer protein liquid is placed in pH value is 5.5 ~ 8.0 salt concn is damping fluid under 150 ~ 1000mM condition, completely freezing under-20 ~-80 DEG C of conditions, preferably after freezing 24 hours, place room temperature again to melt to protein stoste, obtain the HPV18L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.

on the other hand, present invention also offers the pentamer of HPVL1, VLP and comprise the vaccine of pentamer or VLPthe application of composition in the medicine of preparation prevention HPV infection.

According to the present invention, vaccine of the present invention can adopt the acceptable form of patient, includes but not limited to that injection or nasal cavity or oral cavity suck or vagina administration, optimizing injection and intramuscularly.

the explanation of relational language and explanation in the present invention

According to the present invention, term " escherichia expression system " refers to and is made up of intestinal bacteria (bacterial strain) and carrier, wherein intestinal bacteria (bacterial strain) derive from available on the market, illustrate at this but be not limited to: GI698, ER2566, BL21 (DE3), XA90, DH (5a), B834 (DE3), BLR (DE3).

According to the present invention, term " carrier " word refers to and the polynucleotide of certain coded protein can be inserted wherein and make protein obtain a kind of nucleic acid launch vehicle of expressing.Carrier can by transforming, and transduction or transfection host cell, the genetic material element making it carry obtains expression in host cell.For example, carrier comprises: plasmid; Phage; Coemid etc.

According to the present invention, " vaccine vehicle or carrier " refer to and are selected from one or more, include but not limited to: pH adjusting agent, tensio-active agent, adjuvant, ionic strength toughener term.Such as, pH adjusting agent is illustrated but is not limited to phosphate buffered saline buffer, and tensio-active agent comprises positively charged ion, negatively charged ion or nonionic surface active agent.Illustrate but be not limited to: Polysorbate 80.Adjuvant is illustrated but is not limited to aluminium hydroxide, aluminum phosphate, Fu Shi Freund's complete adjuvant, Fu Shi Freund's incomplete adjuvant etc.Ionic strength toughener is illustrated but is not limited to sodium-chlor.

According to the present invention, term " chromatogram " includes but not limited to: ion-exchange chromatography (such as cation-exchange chromatography, anion-exchange chromatography), hydrophobic interaction chromatograph, adsorption chromatography chromatography (such as hydroxylapatite chromatography), molecular sieve chromatography chromatography (gel-filtration or molecular exclusion chromatography), affinity chromatography method.

According to the present invention, in the restructuring HPVL1 method of protein that the present invention obtains, damping fluid refers to a kind of solution that greatly can reduce pH amplitude of fluctuation when adding a small amount of acid or alkali and water, include but not limited to Tris damping fluid, phosphate buffered saline buffer, acetate buffer solution, HEPES damping fluid, MOPS damping fluid, citrate buffer, histidine buffering liquid, borate buffer etc.

According to the present invention, described cytoclasis include but not limited to broken by homogenizer, clarifixator is broken, ultrasonication, grinding, high-pressure extrusion, in N,O-Diacetylmuramidase process one or multinomial method realize;

According to the present invention, in the restructuring HPVL1 method of protein that the present invention obtains, salt used includes but not limited to it is neutral salt, particularly an alkali metal salt, ammonium salt, hydrochloride, vitriol, supercarbonate, one or more in phosphoric acid salt or hydrophosphate, particularly NaCI, KCl, CaCl2, NH4Cl, KCI, NH4CI, MgSO4, (NH4) 2SO4.Preferred NaCI.Reductive agent used includes but not limited to DTT, 2 mercapto ethanol.Amount used includes but not limited to 2mM ~ lO0mM, preferably 10 ~ 15mM.

Beneficial effect

The invention provides a kind of synthetic gene, this gene order carried out codon optimized nucleotide sequence according to colibacillary codon preference, this sequence encoding HPVL1 protein amino acid sequence.Research finds that the nucleotide sequence of codon optimization is significantly increased relative to the expression amount of the L1 albumen without codon optimized nucleotide sequence.

Escherichia expression system disclosed by the invention have expression amount high, be easy to cultivate and operation and the advantage such as production cost is low.But only use this expression system to be still difficult to directly obtain the HPVL1 albumen of great amount of soluble, its reason is the as easy as rolling off a log formation inclusion body of L1 albumen, i.e. the insoluble polymer of abiology activity.In addition, even if obtain a large amount of inclusion bodys, in order to obtain the albumen of biologic activity, also sex change, renaturation process must be carried out to inclusion body, the albumen of this process often large losses.In order to solve this difficult problem, the present invention adopts integration technology, by L1 gene with have assist protein correctly to fold albumen as glutathione S-transferase (GST), SUMO, MBP, 6*His-SUMO or GST-SUMO etc. carry out amalgamation and expression, not only the solubility of albumen and yield increase, and GST-SUMO-HPVL1, 6*His-SUMO-HPVL1 makes do not have the residual of exogenous amino acid at HPVL1 protein N terminal, find the fusion tag that GST-SUMO wherein expresses as recombinant protein HPVL1 and molecular chaperones simultaneously, there is protease inhibitor hydrolysis, remarkable increase expression of recombinant proteins amount and promotion target protein correctly fold, improve the functions such as solubility.Therefore the technological line that the present invention adopts have employed label protein integration technology when building HPVL1 protein expression vector, the fusion rotein formed by label protein and L1 albumen on the one hand improves the solubility of target protein, improve output, affinity chromatography and proteolytic ferment excision can be utilized to merge the purifying feature that matter stamp methods carries out target protein by GST fusion tag on the other hand, thus achieve single step purification from the cell pyrolysis liquid of broad categories and can obtain the HPVL1 albumen that purity reaches more than 70%, substantially increase purification efficiency, thus improve the output of end product HPVL1 albumen.

Provided by the inventionly first to express, separation and purification to obtain after highly purified HPVL1 pentamer albumen Artificial Control assembling again and form the technological line of VLP, can solve current known technology exist from foreign protein miscellaneous cytoclasis liquid, direct purification VLP purity is low, degraded ratio is high, the problem that yield is low, obtains high purity pentamer assembled in vitro VLP and VLP preservation condition.

In addition, the present inventor have been surprisingly found that a kind of new assembling condition and method: i.e. cryogenic freezing process construction from part.The VLP obtained by the method inhomogenous for the particle diameter assembled before freeze thawing protein (PdI is greater than 0.1) can be become size coincidence theory expection and also homogeneous, the VLP that PdI is less than 0.1, the VLP that contrast prior art obtains is more stable, and different salt concn, pH value range can be stored in widely in damping fluid, the dilution of final vaccine preparation of being more convenient for and preparation.

The present invention, through the HPVL1VLP protein of gained of recombinating, has good immunogenicity, can the neutralizing antibody for homotype HPV of induced high titers, and HPV is to the infection of human body in prevention, is a kind of good vaccine form.

With reference to as detailed below and accompanying drawingafter, these and other aspect of the present invention will be obvious.All reference disclosed herein all completely to be quoted as a reference at this.

Accompanying drawing explanation

Fig. 1: GST-HPV18L1 protein is affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is protein mass marker Lane: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kdat, and left swimming lane is the resin of affine absorption GST-L1, and right swimming lane is the resin of GST and L1 after enzymolysis.

Fig. 2: GST-SUMO-HPV18L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption GST-SUMO-L1, and right swimming lane is the resin of GST-SUMO and L1 after enzymolysis.

Fig. 3: MBP-HPV18L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption MBP-L1, and right swimming lane is the resin of MBP and L1 after enzymolysis.

Fig. 4: 6*HIS-SUMO-HPV18L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption 6*HIS-SUMO-L1, and right swimming lane is the resin of 6*HIS-SUMO and L1 after enzymolysis.The fused albumen with 6*HIS-SUMO label is not cut by gel electrophoresis figure display proteolytic enzyme.

Fig. 5: the restructuring HPV18L1 pentamer protein s DS-PAGE gel electrophoresis figure of the present invention after molecular sieve chromatography purifying.M swimming lane is protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and another swimming lane is HPVL1 albumen.

The dynamic light scattering observed result of Fig. 6: HPV18L1 pentamer.The particle size diameter of result display pentamer is 13.14nM, size-grade distribution PdI is 0.030.

The dynamic light scattering observed result of Fig. 7: HPV18L1VLP.The particle size diameter of result display VLP is 61.56nM, size-grade distribution PdI is 0.041.

The transmission electron microscope photo of Fig. 8: HPV18L1 pentamer albumen.

The transmission electron microscope photo of Fig. 9: HPV18L1VLP albumen.

The high-pressure liquid phase molecular sieve chromatography figure of Figure 10: HPV18L1 pentamer protein, shows in figure and is greater than 98% through highly purified L1 pentamer lipidated protein.

The high-pressure liquid phase molecular sieve chromatography figure of Figure 11: HPV18L1VLP protein, shows in figure and is greater than 98% through highly purified VLP lipidated protein.

After each experimental group vaccinated mice of Figure 12: HPV18L1 pentamer, at second time booster immunization after 4 weeks, detect the average titer level of neutralizing antibody.

After Figure 13: HPV18L1VLP each experimental group vaccinated mice, at second time booster immunization after 4 weeks, detect the average titer level of neutralizing antibody.

Below in conjunction with embodiment, the present invention is illustrated description further.These embodiments are nonrestrictive.

EXAMPLE l: the Design and synthesis of codon optimized HPVL1 gene

Gene order derives from published various HPV sequence on PUBMED.With reference to intestinal bacteria, to selected various HPVDNA sequence, all HPVDNA sequences of codon optimized rear synthesis are carried out to the preference of genetic transcription codon.According to synthetic DNA primers, synthetic gene is utilized to carry out pcr amplification for template.The codon optimised sequence of gained is verified by determined dna sequence.

The various DNA sequence dna of HPV before optimizing and after optimizing:

SEQNO.1: the DNA sequence dna of the HPV18 type L1 before optimization

SEQNO.2: the DNA sequence dna of the HPV18 type L1 after optimization

Embodiment 2: the structure of recombinant vectors pGEX-6P-1-GST-HPV18L1 and qualification:

The DNA fragmentation primer of amplification HPV18L1: (restriction enzyme site is BamHI and XhoI respectively)

Forward-HPV18L1-ApaI:5’ACTTCA GGATCCATGGCTCTGTGGCGTCCGTCTG

Reverse-HPV18L1-XhoI:5’ATCTCA CTCGAGCTATTTACGAGCACGAACACGAAC

pcr amplification reaction system:10xPfubuffer20 μ L, Pfu enzyme 4 μ L, 10mMdNTP2.5 μ L, 5 ' Primer (5 μMs) 10 μ L, 3 ' Primer (5 μMs) 10 μ L, template DNA 50ng, adds d2H2O to 200 μ L.

gene PCR amplification condition:95 DEG C of 3min; 95 DEG C of 30sec, 58 DEG C of 30sec, 72 DEG C of 4min; Circulate 32 times; 72 DEG C of 10min.

L1 gene fragment containing BamHI and XhoI restriction enzyme site and vector pGEX-6P-1 are carried out the process of BamHI/XhoI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGEX-6P-1 containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order afterwards by Shanghai Sheng Gong biotech firm, the nucleotides sequence obtaining merging restructuring GST-HPV18-L1 protein is classified as SEQNO.3, and aminoacid sequence is SEQNO.8.

With reference to the fusion recombinant vectors GST-HPV-L1 of this embodiment method preparation with GST-label, its gene order SEQNO.11.

Embodiment 3: recombinant vectors pGEX-6P-1m-GST-SUMO-HPV18L1 vector construction

PGEX-6p-1m vector construction: the unique ApaI restriction enzyme site being carrier for the ApaI restriction enzyme site (GGGCCC) making multienzyme cut location proximate, under the prerequisite not changing lacI gene protein expressed sequence, by the synonym GGT that the Gly codon GGC in another ApaI recognition sequence GGGCCC of commercially available pGEX-6p-1 carrier is changed into it by point mutation technology, ApaI(3890 can be eliminated).ApaI is become can be used to the site of inserting expressing gene by such transformation.

The DNA fragmentation primer of amplification SUMO: (restriction enzyme site is ApaI and BamHI respectively)

Forward-SUMO-ApaI:ACTTCA GGGCCCTCTGACCAGGAAGCTAAACCGTC

Reverse-SUMO-BamHI:CGC GGATCCACCGGTCTGTTCCTGGTAAAC

The DNA fragmentation primer of amplification HPV18L1: (restriction enzyme site is BamHI and XhoI respectively)

Forward-HPV18L1-ApaI:5’ACTTCA GGATCCATGGCTCTGTGGCGTCCGTCTG

Reverse-HPV18L1-XhoI:5’ATCTCA CTCGAGCTATTTACGAGCACGAACACGAAC

pcr amplification reaction system:10xPfubuffer20 μ L, Pfu enzyme 4 μ L, 10mMdNTP2.5 μ L, 5 ' Primer (5 μMs) 10 μ L, 3 ' Primer (5 μMs) 10 μ L, template DNA 50ng, adds d2H2O to 200 μ L.

gene PCR amplification condition:95 DEG C of 1.5min; 95 DEG C of 30sec, 58 DEG C of 30sec, 72 DEG C of 1min; Circulate 32 times; 72 DEG C of 10min.

the same above-described embodiment of gene PCR amplification condition.

Enzyme cuts connection: the SUMO gene fragment containing ApaI and BamHI restriction enzyme site and vector pGEX-6P-1m are carried out the process of ApaI/BamHI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGEX-6P-1m containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

Transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtaining merging recombinant vectors pGSTSUMO-6p-1m.

Enzyme cuts connection again: the L1 gene fragment containing BamHI and Xho1 restriction enzyme site and recombinant vectors pGSTSUMO-6p-1m are carried out the process of BamHI/Xho1 double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGSTSUMO-6p1m containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

Again transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening is carried out enlarged culturing and carries out the extraction of plasmid, checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtain the fusion recombinant vectors GST-SUMO-L1 with GST-SUMO label, its gene order SEQNO.4, aminoacid sequence is SEQNO.9.

With reference to the fusion recombinant vectors GST-SUMO-L1 of this embodiment method preparation with GST-SUMO label, its gene order SEQNO.12.

Embodiment 4: the structure of recombinant vectors pMAL-MBP-HPV18L1

The DNA fragmentation primer of amplification HPV18L1: (restriction enzyme site is EcoRI and HindIII respectively)

Forward-HPV18L1-EcoRI:5’ACTTCA GAATTCATGGCTCTGTGGCGTCCGTCTG

Reverse-HPV18L1-HindIII:5’ATCTCA AAGCTTCTATTTACGAGCACGAACACGAAC

L1 gene fragment containing EcoRI and HindIII restriction enzyme site and carrier pMAL are carried out the process of EcoRI/HindIII double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pMAL containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order afterwards by Shanghai Sheng Gong biotech firm, obtain the gene order SEQNO.5 merging restructuring MBP-HPV18-L1 protein, aminoacid sequence is SEQNO.10.

With reference to the fusion recombinant vectors MBP-HPV-L1 of this embodiment method preparation with MBP label, its gene order SEQNO.13.

Embodiment 5: the structure of recombinant vectors pET28a-6*His-HPV18L1

The DNA fragmentation primer of amplification HPV18L1: (restriction enzyme site is NdeI and XhoI, pET28a respectively)

Forward-HPV18L1-NdeI:5’GACTTCA CATATGATGGCTCTGTGGCGTCCGTCTG

Reverse-HPV18L1-XhoI:5’CATCTCA CTCGAGCTATTTACGAGCACGAACACGAAC

L1 gene fragment containing NdeI and XhoI restriction enzyme site and carrier pMAL are carried out the process of NdeI/XhoI double digestion, utilizes T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pET28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Shanghai Sheng Gong biotech firm afterwards, obtaining the gene order SEQNO.6 merging restructuring MBP-HPV18-L1 protein.

Embodiment 6: recombinant vectors 6*His-SUMO-HPV18L1 vector construction

The DNA fragmentation primer of amplification SUMO: (restriction enzyme site is NdeI and BamHI respectively)

Forward-SUMO-NdeI:GGAATTC CATATGTCTGACCAGGAAGCTAAACCGTC

Reverse-SUMO-BamHI:CGC GGATCCACCGGTCTGTTCCTGGTAAAC

The DNA fragmentation primer of amplification HPV18L1: (restriction enzyme site is BamHI and XhoI respectively)

Forward-HPV18L1-ApaI:5’ACTTCA GGATCCATGGCTCTGTGGCGTCCGTCTG

Reverse-HPV18L1-XhoI:5’ATCTCA CTCGAGCTATTTACGAGCACGAACACGAAC

SUMO gene, L1 gene PCR amplification condition, reaction system are with described in above-described embodiment.

Enzyme cuts connection: the SUMO gene fragment containing NdeI and BamHI restriction enzyme site and carrier pET-28a are carried out the process of NdeI/BamHI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pET28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

Transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtaining merging recombinant vectors pETSUMO-28a.

Enzyme cuts connection again: the L1 gene fragment containing BamHI and Xho1 restriction enzyme site and recombinant vectors pETSUMO-28a are carried out the process of BamHI/Xho1 double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pETSUMO-28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.

Again transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Shanghai Sheng Gong biotech firm afterwards, obtaining the gene order SEQNO.7 merging restructuring MBP-HPV18-L1 protein.

Embodiment 7: restructuring HPVL1 pentamer protein expression

By the recombinant vectors transformation of E. coli BL21 host cell of correct for sequencing result embodiment 2,3,4,5 and 6, and carry out the expression of HPVL1 albumen as the engineering bacteria of expressing recombinant protein.Recombinant base is 2YT substratum (10g/L tryptone; 5g/L yeast powder; 10g/LNaCl).Picking contains the thalline list spot of recombinant plasmid in 10ml2YT substratum (containing 100 μ g/ml penbritins), and 230 revs/min (rpm), 37 DEG C of shaking culture are spent the night.Switching 5ml spends the night bacterium in 500ml(containing 100 μ g/ml penbritins) in 2YT liquid nutrient medium, 37 DEG C of concussions are cultured to recombinant bacterial strain when growing to OD600nm ≈ 0.4 ~ 1, add the IPTG induction of final concentration 0.2mM, under the condition of 28 DEG C, carry out the abduction delivering of more than 6h recombinant protein.

Cell harvesting and fragmentation :carry out centrifugal to fermenting culture, abandon supernatant, results bacterial sediment, weighs; Use bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) washing precipitation, is then resuspended in bufferL and is carried out ultrasonic disruption, carries out centrifugal (16000rpm subsequently by supercentrifuge to broken bacterium liquid, 30min, 4 DEG C), collect supernatant liquor.

Embodiment 8: restructuring HPVL1 pentamer albumen is in the detection of expression in escherichia coli amount

Before adopting ELISA sandwich assay to detect affinity chromatography loading, Tag-HPVL1 pentamer albumen is in expression in escherichia coli amount, sample and trial-product:

coated antibody:make anti-HPV18L1 mouse monoclonal by oneself.

reference substance:make highly purified HPV18L1 albumen by oneself.

trial-product:with sample diluting liquid by trial-product tag-HPV18L1be diluted to concentration in reference substance gradient dilution concentration range.

enzyme labelled antibody:the anti-HPV18L1 albumen of rabbit of homemade horseradish peroxidase-labeled resists more.

result calculates:calculate the mean value of parallel hole, with reference substance series concentration OD ₄₅₀absorption value makes straight-line equation to its corresponding L1 proteantigen, and between Duplicate Samples sample wells, the variation coefficient must not be greater than 10%, linear regression equation R ²must not 0.980 be less than, by the OD of trial-product ₄₅₀absorption value substitutes into Equation for Calculating and goes out trial-product L1 proteantigen content after dilution, then is multiplied by corresponding extension rate and is L1 proteantigen content in trial-product, in table 1.

Tag-HPVL1 proteantigen content after table 1 detects and expresses

Embodiment 9: restructuring HPVL1 pentamer protein affinity chromatography

affinity chromatography with GST label recombinant protein:gST agarose affinity chromatography medium 5ml is loaded in affinity column, with bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) balance chromatography column, then in loading embodiment 8 with the protein liquid of GST or GST-SUMO label, after with BufferL be washed till without protein flow out, affine complete.With 5mLBufferL suspension affinity media, sampling detects and in conjunction with the total amount of L1 protein in calculation medium.

affinity chromatography with MBP label recombinant protein:amylose-Resin affinity chromatography medium 5ml is loaded in affinity column, with bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) balance chromatography column, then in loading embodiment 8 with the protein liquid of GST or GST-SUMO label, after with BufferL be washed till without protein flow out, affine complete.With 5mLBufferL suspension affinity media, sampling detects and in conjunction with the total amount of L1 protein in calculation medium.

affinity chromatography with 6*HIS label recombinant protein:get 5mlNi-NTA gel dress post, post slowly adds the balance liquid (50mmol/LNaH2PO4,300mmol/LNacl, 20mmol/Limidazole adjust pH value to 8 with NaOH) of 10 times of column volumes, and fully to balance Ni-NTA gel, flow velocity is 1ml/min.The supernatant liquor with 6*His label after filtering in Example 8, after entering gel completely, continue detergent gel with the balance liquid of 10 times of column volumes, preservation flow velocity is 1ml/min.Be eluted to balance liquid and flow out without protein, affine complete.Sampling detects and in conjunction with the total amount of L1 protein in calculation medium.

Embodiment 10: the enzyme of restructuring Tag-HPVL1 protein cuts purifying

Enzyme amount is added according to target protein matter and proteolytic enzyme mass ratio 100:1, protein HRV 3CP wherein with GST-HPV-L1 is cut, protein with GST-SUMO-HPV-L1 and 6*His-SUMO-HPV-L1 SENP1 proteolytic cleavage, protein with Mbp-HPV-L1 FactorXa proteolytic cleavage, protein with 6*His-HPV-L1 Thrombin proteolytic cleavage, respectively after Double digestion 2h, wash-out collects the HPV18L1 pentamer protein soln of gained after each proteolytic cleavage respectively.

3C enzyme enzyme is cut the L1 protein soln SDS-PAGE detected through gel electrophoresis after GST label, the results are shown in Figure 1 affinity chromatography electrophoresis result, experiment shows, the target protein of 90% can be cut.Fig. 2 is the protein of SENP1 proteolytic cleavage with GST-SUMO-HPV-L1, uses SDS-PAGE detected through gel electrophoresis.Fig. 3 is the protein of FactorXa proteolytic cleavage with Mbp-HPV-L1, uses SDS-PAGE detected through gel electrophoresis.Fig. 1-Fig. 3 obtains the HPV18L1 albumen of 55kDa.

Thrombin proteolytic enzyme does not cut the protein of 6*His-HPV-L1; Cut the protein soln SDS-PAGE detected through gel electrophoresis of 6*His-SUMO-L1 with SENP1 enzyme, the results are shown in Figure 4, display SENP1 proteolytic enzyme fails to cut the fused albumen with 6*His-SUMO label.

Embodiment 11: restructuring HPVL1 pentamer protein purification

Molecular sieve chromatography purifying: the enzyme that a upper embodiment is collected is cut the HPV18L1 pentamer protein after purifying and carries out purifying respectively, can first through the HPV18L1 pentamer protein of ion-exchange chromatography collection, or directly use the gel filter medium of Superdex200 (production of GE company) to carry out further sieve chromatography without ion-exchange step, molecular sieve moving phase is pH8.0,10mMTris, 100mMNaCl, collects the cut of HPV18L1 pentamer protein ultraviolet absorption peak.

Working sample purity after purifying: SDS-PAGE detected through gel electrophoresis is used in the protein soln collected sampling, target protein matter HPV18L1 pentamer final purity after sieve chromatography purifying is all greater than 98%, refer to Fig. 5, the restructuring HPV18L1 pentamer protein s DS-PAGE gel electrophoresis figure after molecular sieve chromatography purifying.

Working sample protein concentration: carry out protein concentration detection by Bradford method, standard specimen 2mg/mlBAS preparation is used to be diluted to 500ug/ul from 100ug/ul, example reaction system gets the BSA+200ulBradford working fluid of 10ul dilution: typical curve is y=0.0013x-0.0294, R2=0.9986, the OD of working sample ₅₉₅, substitute into typical curve, the protein concentration of calculation sample, the results are shown in Table 2.

Table 2Bradford method detects restructuring HPV18L1 pentamer protein concentration

Note: sample sets 1 is that GST-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification; Sample sets 2 is that GST-SUMO-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification; Sample sets 3 is that Mbp-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification.

Embodiment 12: restructuring HPV18L1 pentamer protein group dresses up VLP

Be placed under following salt concn (NaCl) and pH value condition, HPVL1 pentamer solution example group 1,2 and 3, place after stablizing, use the dynamic light scattering particle instrument of Malvern ZetasizerNanoZS, (size distribution FACTOR P dI value is grain size dispersity index, is less than 0.05 for highly homogeneous sample to carry out particle diameter and particle size distribution measuring; 0.05 ~ 0.1 is as the criterion homogeneous sample, and 0.1 ~ 0.3 is the poor sample of homogeneity, is greater than 0.3 for inhomogenous sample), the assembling of HPV18L1 pentamer albumen obtains the VLP(of uniform particle diameter pdI < 0.05).

The droplet measurement of HPV18L1VLP is assembled under the different pH of table 3 and salt concentration conditions

Note: sample sets 1 is that GST-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification; Sample sets 2 is that GST-SUMO-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification; Sample sets 3 is that Mbp-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification.

Embodiment 13: dynamic light scattering (DLS) is to L1 pentamer and VLP protein particle size determination

Instrument is the dynamic light scattering particle instrument of Malvern ZetasizerNanoZS, get HPV18L1 pentamer that each sample group finally obtains and HPV18L1VLP protein detects, survey the homogeneity that median size and monodispersity index PdI(show protein), illustrate the L1 pentamer that each group of sample is finally prepared and VLP albumen homogeneous.The pentamer protein that wherein sample sets 2 is finally obtained and the HPV18L1VLP protein size distribution that its assembling obtains refer to accompanying drawing 6 He7.

The preparation of embodiment 14:HPV18L1 pentamer and VLP

According to the technology that the above embodiment of the present invention 1-13 adopts, preparation has sequence 11,12, the HPV18L1 albumen of 13, above albumen all can obtain the albumen that purity reaches more than 98% by purifying, obtains the HPV18L1 pentamer albumen of median size 10 ~ 15nmPdI<0.1.Further assembling obtains the HPV18L1VLP albumen of median size 45 ~ 65nmPdI<0.1.

The morphologic detection of embodiment 15:HPV18L1 pentamer and VLP

transmission electron microscope observing:the HPV18L1-VLP protein that the HPV18L1 pentamer protein obtained by each purifying in embodiment, assembling obtain, utilizes transmission electron microscope platform to observe by Instite of Biophysics, Chinese Academy of Sciences.Freezing sample preparation and flow process of taking pictures:

1) by liquid nitrogen box filled with liquid nitrogen, when liquid level does not seethe with excitement, ethane is slowly injected the copper bowl of cooling, make it to be cooled to liquid state.

2) copper mesh is done wetting ability process at PDC-32 type plasma cleaning device.

3) in the freezing sample preparation device of VitrobotTMMarkIV, by the pentamer of 3.5 μ L and VLP sample adsorption in 300 object QUANTIFOIL copper mesh, after water suction 4s, by the freezing sample of liquid ethane.

4) rapid being transferred in liquid nitrogen by sample is preserved.

5), when collecting freezing photo, electron dose is 20e-/2.Data are by the GatanUltraScan4000CCD record of the 300kVTitanKrios transmission electron microscope of 300KV.Acceleration voltage is 300kV.

Result shows, in HPV18L1 pentamer protein example group, and the pentamer albumen of about the 10nm that visible a large amount of diameter conforms to theoretical size in the visual field; In HPV18L1-VLP protein example group, a large amount of diameters that visible particle size conforms to theory are the virus-like particle (VLP) of about 50nm, uniformity.After wherein GST-SUMO set of tags (sample sets 2) enzyme cuts purifying, the transmission electron microscope photo of HPV18L1 pentamer gained sample is shown in accompanying drawingthe transmission electron microscope photo of the VLP albumen that 8, Mbp set of tags (sample sets 3) enzyme is assembled after cutting purifying is again shown in accompanying drawing9.

Embodiment 16:HPV18L1 protein stoste purity detecting

Size Exclusion High Performance liquid chromatogram measuring: chromatographic column AgilentBioSEC-5um, 2000,7.8 × 300mm, column volume is about 15m1, molecular weight ranges >=lO, OOOkDa; With the 0.1mol/L phosphate buffered saline buffer of pH6.8 (take Sodium phosphate dibasic 25.8g, SODIUM PHOSPHATE, MONOBASIC 4.37g, add ultrapure water and make dissolving, with phosphoric acid adjust pH to 6.8, ultrapure water constant volume becomes 1000ml) be moving phase; Flow velocity is 1ml/min; Determined wavelength 280nm; Column temperature 25 DEG C, applied sample amount must not be less than 20ug, and sample main peak theoretical plate number is not less than 1000, and tailing factor is less than 2.0, continuous sample introduction 5 pin, and the relative standard deviation of peak area must not be greater than 3%.

Get the 2 groups of HPV18L1 finally obtained of the sample after purifying pentamerwith assembling after vLPprotein stoste, weaker concn is 1mg/ml respectively, and applied sample amount 20ul injects high pressure liquid chromatograph, detects according to the method described above, and by area normalization method calculated purity, all process lipidated proteins are all greater than 98%, the results are shown in accompanying drawing10 and table 4, accompanying drawing11 and table 5.

The HPLC lipidated protein of table 4HPV18L1 pentamer detects

After table 5HPV18L1 assembling vLPhPLC lipidated protein detect

Peak	Retention time	Area	Area %
				1	13.515	3792004	100.00
Amount to		3792004	100.00

Embodiment 17:HPVVLP stability experiment

The HPV18VLP protein each sample sets finally obtained, under the buffer conditions of following table, is placed 14 days to 28 days at 25 DEG C, is carried out droplet measurement, the results are shown in following table, prove that HPV18VLP is at pH5.0 to 5.9, deposit stable under salt concn 500 ~ 2000mM.Sample sets 3 gained HPV18VLP is at pH5.0 to 5.9, and after placing 14-28 days under salt concn 500 ~ 2000mM, detected result refers to as following table.

Table 6HPV18L1VLP places 14-28 days droplet measurement results at 25 DEG C

Embodiment 18: preparation contains the univalent vaccine of HPVL1 pentamer or VLP

HPV18L1 pentamer containing each sample sets or VLP albumen stoste are carried out absorption preparation with aluminum hydroxide adjuvant normal saline solution according to albumen and aluminium content 1:10 ratio respectively and can obtain recombinate HPVL1 protein pentamer or VLP vaccine, stand-by 4 DEG C of preservations.

The immunogenicity determining of embodiment 19:HPVL1 pentamer and VLP

Get above-mentioned L1 pentamer or VLP vaccine respectively, the physiological saline adding sterilizing is diluted to pentamer or the VLP protein vaccine of 20 μ g/ml concentration respectively, with every 0.1ml intramuscular injection BALB/c mouse, often organizes 10.Mouse every 4 weeks booster immunizations once, are total to immunity 2 times.Booster immunization is after 4 weeks, and for the NAT of homotype HPV in the mice serum after adopting pseudovirus cell Neutralizing test method to measure each immunity respectively, result is as attached figure12, shown in 13.

Result shows, HPVL1 pentamer and VLP protein vaccination mouse, after second immunisation, 4 weeks neutralizing antibodies can reach very high level.The results show, the VLP vaccine of HPVL1 pentamer and assembling all can produce neutralizing antibody in animal body, illustrate that HPVL1 pentamer and VLP protein vaccine all have immunogenicity in human clinical trial, the disease that HPV homologous virus causes can be prevented.

SEQUENCELISTING

<110> Beijing Health Guard Biotechnology Co., Ltd.

<120>18 type recombinant human papilloma virus virus-like particle and preparation method thereof

<130>2014

<160>13

<170>PatentInversion3.3

<210>1

<211>1524

<212>DNA

<213> artificial sequence

<400>1

atggctttgtggcggcctagtgacaataccgtatatcttccacctccttctgtggcacga60

gttgtaaataccgatgattatgtgactcgcacaagcatattttatcatgctggcagctct120

agattattaactgttggtaatccatattttagggttcctgcaggtggtggtaataagcag180

gatattcctaaggtttcggcataccaatatagagtatttagggtgcagttacctgaccca240

aataaatttggtttacctgataatagtatttataatcctgaaacacaacgtttagtgtgg300

gcctgtgctggagtggaaattggccgtggtcagcctttaggtgttggccttagtgggcat360

cccttttataataaattagatgacactgaaagttcccatgccgccacgtctaatgtttct420

gaggacgttagggacaatgtgtctgtagattataagcagacacagttatgtattttgggc480

tgtgcccctgctattggggaacactgggctaaaggcactgcttgtaaatcgcgtccttta540

tcacagggcgattgcccccctttagaacttaaaaacacagttttggaagatggtgatatg600

gtagatactggatatggtgccatggactttagtacattgcaagatactaaatgtgaggta660

ccattggatatttgtcagtctatttgtaaatatcctgattatttacaaatgtctgcagat720

ccttatggggattccatgtttttttgcttacggcgtgagcagctttttgctaggcatttt780

tggaatagggcaggtactatgggtgacactgtgcctcaatccttatatattaaaggcaca840

ggtatgcgtgcttcacctggcagctgtgtgtattctccctctccaagtggctctattgtt900

acctctgactcccagttgtttaataaaccatattggttacataaggcacagggtcataac960

aatggtgtttgctggcataatcaattatttgttactgtggtagataccactcgcagtacc1020

aatttaacaatatgtgcttctacacagtctcctgtacctgggcaatatgatgctaccaaa1080

tttaagcagtatagcagacatgttgaggaatatgatttgcagtttatttttcagttgtgt1140

actattactttaactgcagatgttatgtcctatattcatagtatgaatagcagtatttta1200

gaggattggaactttggtgttccccccccgccaactactagtttggtggatacatatcgt1260

tttgtacaatctgttgctattacctgtcaaaaggatgctgcaccggctgaaaataaggat1320

ccctatgataagttaaagttttggaatgtggatttaaaggaaaagttttctttagactta1380

gatcaatatccccttggacgtaaatttttggttcaggctggattgcgtcgcaagcccacc1440

ataggccctcgcaaacgttctgctccatctgccactacgtcttctaaacctgccaagcgt1500

gtgcgtgtacgtgccaggaagtaa1524

<210>2

<211>1521

<212>DNA

<213> artificial sequence

<400>2

atggctctgtggcgtccgtctgacaacaccgtttacctgccgccgccgtctgttgctcgt60

gttgttaacaccgacgactacgttacccgtacctctatcttctaccacgctggttcttct120

cgtctgctgaccgttggtaacccgtacttccgtgttccggctggtggtggtaacaaacag180

gacatcccgaaagtttctgcttaccagtaccgtgttttccgtgttcagctgccggacccg240

aacaaattcggtctgccggacaactctatctacaacccggaaacccagcgtctggtttgg300

gcttgcgctggtgttgaaatcggtcgtggtcagccgctgggtgttggtctgtctggtcac360

ccgttctacaacaaactggacgacaccgaatcttctcacgctgctacctctaacgtttct420

gaagacgttcgtgacaacgtttctgttgactacaaacagacccagctgtgcatcctgggt480

tgcgctccggctatcggtgaacactgggctaaaggtaccgcttgcaaatctcgtccgctg540

tctcagggtgactgcccgccgctggaactgaaaaacaccgttctggaagacggtgacatg600

gttgacaccggttacggtgctatggacttctctaccctgcaggacaccaaatgcgaagtt660

ccgctggacatctgccagtctatctgcaaatacccggactacctgcagatgtctgctgac720

ccgtacggtgactctatgttcttctgcctgcgtcgtgaacagctgttcgctcgtcacttc780

tggaaccgtgctggtaccatgggtgacaccgttccgcagtctctgtacatcaaaggtacc840

ggtatgcgtgcttctccgggttcttgcgtttactctccgtctccgtctggttctatcgtt900

acctctgactctcagctgttcaacaaaccgtactggctgcacaaagctcagggtcacaac960

aacggtgtttgctggcacaaccagctgttcgttaccgttgttgacaccacccgttctacc1020

aacctgaccatctgcgcttctacccagtctccggttccgggtcagtacgacgctaccaaa1080

ttcaaacagtactctcgtcacgttgaagaatacgacctgcagttcatcttccagctgtgc1140

accatcaccctgaccgctgacgttatgtcttacatccactctatgaactcttctatcctg1200

gaagactggaacttcggtgttccgccgccgccgaccacctctctggttgacacctaccgt1260

ttcgttcagtctgttgctatcacctgccagaaagacgctgctccggctgaaaacaaagac1320

ccgtacgacaaactgaaattctggaacgttgacctgaaagaaaaattctctctggacctg1380

gaccagtacccgctgggtcgtaaattcctggttcaggctggtctgcgtcgtaaaccgacc1440

atcggtccgcgtaaacgttctgctccgtctgctaccacctcttctaaaccggctaaacgt1500

gttcgtgttcgtgctcgtaaa1521

<210>3

<211>2214

<212>DNA

<213> artificial sequence

<400>3

atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60

ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120

tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180

ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240

atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300

gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360

gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420

acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480

gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540

aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600

tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660

ctggaagttctgttccaggggcccctgggatccatggctctgtggcgtccgtctgacaac720

accgtttacctgccgccgccgtctgttgctcgtgttgttaacaccgacgactacgttacc780

cgtacctctatcttctaccacgctggttcttctcgtctgctgaccgttggtaacccgtac840

ttccgtgttccggctggtggtggtaacaaacaggacatcccgaaagtttctgcttaccag900

taccgtgttttccgtgttcagctgccggacccgaacaaattcggtctgccggacaactct960

atctacaacccggaaacccagcgtctggtttgggcttgcgctggtgttgaaatcggtcgt1020

ggtcagccgctgggtgttggtctgtctggtcacccgttctacaacaaactggacgacacc1080

gaatcttctcacgctgctacctctaacgtttctgaagacgttcgtgacaacgtttctgtt1140

gactacaaacagacccagctgtgcatcctgggttgcgctccggctatcggtgaacactgg1200

gctaaaggtaccgcttgcaaatctcgtccgctgtctcagggtgactgcccgccgctggaa1260

ctgaaaaacaccgttctggaagacggtgacatggttgacaccggttacggtgctatggac1320

ttctctaccctgcaggacaccaaatgcgaagttccgctggacatctgccagtctatctgc1380

aaatacccggactacctgcagatgtctgctgacccgtacggtgactctatgttcttctgc1440

ctgcgtcgtgaacagctgttcgctcgtcacttctggaaccgtgctggtaccatgggtgac1500

accgttccgcagtctctgtacatcaaaggtaccggtatgcgtgcttctccgggttcttgc1560

gtttactctccgtctccgtctggttctatcgttacctctgactctcagctgttcaacaaa1620

ccgtactggctgcacaaagctcagggtcacaacaacggtgtttgctggcacaaccagctg1680

ttcgttaccgttgttgacaccacccgttctaccaacctgaccatctgcgcttctacccag1740

tctccggttccgggtcagtacgacgctaccaaattcaaacagtactctcgtcacgttgaa1800

gaatacgacctgcagttcatcttccagctgtgcaccatcaccctgaccgctgacgttatg1860

tcttacatccactctatgaactcttctatcctggaagactggaacttcggtgttccgccg1920

ccgccgaccacctctctggttgacacctaccgtttcgttcagtctgttgctatcacctgc1980

cagaaagacgctgctccggctgaaaacaaagacccgtacgacaaactgaaattctggaac2040

gttgacctgaaagaaaaattctctctggacctggaccagtacccgctgggtcgtaaattc2100

ctggttcaggctggtctgcgtcgtaaaccgaccatcggtccgcgtaaacgttctgctccg2160

tctgctaccacctcttctaaaccggctaaacgtgttcgtgttcgtgctcgtaaa2214

<210>4

<211>2496

<212>DNA

<213> artificial sequence

<400>4

atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60

ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120

tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180

ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240

atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300

gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360

gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420

acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480

gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540

aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600

tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660

ctggaagttctgttccaggggccctctgaccaggaagctaaaccgtctaccgaagacctg720

ggtgacaaaaaagaaggtgaatacatcaaactgaaagttatcggtcaggactcttctgaa780

atccacttcaaagttaaaatgaccacccacctgaaaaaactgaaagaatcttactgccag840

cgtcagggtgttccgatgaactctctgcgtttcctgttcgaaggtcagcgtatcgctgac900

aaccacaccccgaaagaactgggtatggaagaagaagacgttatcgaagtttaccaggaa960

cagaccggtggatccatggctctgtggcgtccgtctgacaacaccgtttacctgccgccg1020

ccgtctgttgctcgtgttgttaacaccgacgactacgttacccgtacctctatcttctac1080

cacgctggttcttctcgtctgctgaccgttggtaacccgtacttccgtgttccggctggt1140

ggtggtaacaaacaggacatcccgaaagtttctgcttaccagtaccgtgttttccgtgtt1200

cagctgccggacccgaacaaattcggtctgccggacaactctatctacaacccggaaacc1260

cagcgtctggtttgggcttgcgctggtgttgaaatcggtcgtggtcagccgctgggtgtt1320

ggtctgtctggtcacccgttctacaacaaactggacgacaccgaatcttctcacgctgct1380

acctctaacgtttctgaagacgttcgtgacaacgtttctgttgactacaaacagacccag1440

ctgtgcatcctgggttgcgctccggctatcggtgaacactgggctaaaggtaccgcttgc1500

aaatctcgtccgctgtctcagggtgactgcccgccgctggaactgaaaaacaccgttctg1560

gaagacggtgacatggttgacaccggttacggtgctatggacttctctaccctgcaggac1620

accaaatgcgaagttccgctggacatctgccagtctatctgcaaatacccggactacctg1680

cagatgtctgctgacccgtacggtgactctatgttcttctgcctgcgtcgtgaacagctg1740

ttcgctcgtcacttctggaaccgtgctggtaccatgggtgacaccgttccgcagtctctg1800

tacatcaaaggtaccggtatgcgtgcttctccgggttcttgcgtttactctccgtctccg1860

tctggttctatcgttacctctgactctcagctgttcaacaaaccgtactggctgcacaaa1920

gctcagggtcacaacaacggtgtttgctggcacaaccagctgttcgttaccgttgttgac1980

accacccgttctaccaacctgaccatctgcgcttctacccagtctccggttccgggtcag2040

tacgacgctaccaaattcaaacagtactctcgtcacgttgaagaatacgacctgcagttc2100

atcttccagctgtgcaccatcaccctgaccgctgacgttatgtcttacatccactctatg2160

aactcttctatcctggaagactggaacttcggtgttccgccgccgccgaccacctctctg2220

gttgacacctaccgtttcgttcagtctgttgctatcacctgccagaaagacgctgctccg2280

gctgaaaacaaagacccgtacgacaaactgaaattctggaacgttgacctgaaagaaaaa2340

ttctctctggacctggaccagtacccgctgggtcgtaaattcctggttcaggctggtctg2400

cgtcgtaaaccgaccatcggtccgcgtaaacgttctgctccgtctgctaccacctcttct2460

aaaccggctaaacgtgttcgtgttcgtgctcgtaaa2496

<210>5

<211>2694

<212>DNA

<213> artificial sequence

<400>5

atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt60

ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat120

ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt180

atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc240

accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac300

aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa360

gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg420

aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg480

ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa540

gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt600

aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa660

ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa720

gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt780

ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc840

ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg900

ggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgcc960

actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc1020

tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa1080

gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac1140

aacctcgggatcgagggaaggatttcagaattcatggctctgtggcgtccgtctgacaac1200

accgtttacctgccgccgccgtctgttgctcgtgttgttaacaccgacgactacgttacc1260

cgtacctctatcttctaccacgctggttcttctcgtctgctgaccgttggtaacccgtac1320

ttccgtgttccggctggtggtggtaacaaacaggacatcccgaaagtttctgcttaccag1380

taccgtgttttccgtgttcagctgccggacccgaacaaattcggtctgccggacaactct1440

atctacaacccggaaacccagcgtctggtttgggcttgcgctggtgttgaaatcggtcgt1500

ggtcagccgctgggtgttggtctgtctggtcacccgttctacaacaaactggacgacacc1560

gaatcttctcacgctgctacctctaacgtttctgaagacgttcgtgacaacgtttctgtt1620

gactacaaacagacccagctgtgcatcctgggttgcgctccggctatcggtgaacactgg1680

gctaaaggtaccgcttgcaaatctcgtccgctgtctcagggtgactgcccgccgctggaa1740

ctgaaaaacaccgttctggaagacggtgacatggttgacaccggttacggtgctatggac1800

ttctctaccctgcaggacaccaaatgcgaagttccgctggacatctgccagtctatctgc1860

aaatacccggactacctgcagatgtctgctgacccgtacggtgactctatgttcttctgc1920

ctgcgtcgtgaacagctgttcgctcgtcacttctggaaccgtgctggtaccatgggtgac1980

accgttccgcagtctctgtacatcaaaggtaccggtatgcgtgcttctccgggttcttgc2040

gtttactctccgtctccgtctggttctatcgttacctctgactctcagctgttcaacaaa2100

ccgtactggctgcacaaagctcagggtcacaacaacggtgtttgctggcacaaccagctg2160

ttcgttaccgttgttgacaccacccgttctaccaacctgaccatctgcgcttctacccag2220

tctccggttccgggtcagtacgacgctaccaaattcaaacagtactctcgtcacgttgaa2280

gaatacgacctgcagttcatcttccagctgtgcaccatcaccctgaccgctgacgttatg2340

tcttacatccactctatgaactcttctatcctggaagactggaacttcggtgttccgccg2400

ccgccgaccacctctctggttgacacctaccgtttcgttcagtctgttgctatcacctgc2460

cagaaagacgctgctccggctgaaaacaaagacccgtacgacaaactgaaattctggaac2520

gttgacctgaaagaaaaattctctctggacctggaccagtacccgctgggtcgtaaattc2580

ctggttcaggctggtctgcgtcgtaaaccgaccatcggtccgcgtaaacgttctgctccg2640

tctgctaccacctcttctaaaccggctaaacgtgttcgtgttcgtgctcgtaaa2694

<210>6

<211>1584

<212>DNA

<213> artificial sequence

<400>6

atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat60

atgatggctctgtggcgtccgtctgacaacaccgtttacctgccgccgccgtctgttgct120

cgtgttgttaacaccgacgactacgttacccgtacctctatcttctaccacgctggttct180

tctcgtctgctgaccgttggtaacccgtacttccgtgttccggctggtggtggtaacaaa240

caggacatcccgaaagtttctgcttaccagtaccgtgttttccgtgttcagctgccggac300

ccgaacaaattcggtctgccggacaactctatctacaacccggaaacccagcgtctggtt360

tgggcttgcgctggtgttgaaatcggtcgtggtcagccgctgggtgttggtctgtctggt420

cacccgttctacaacaaactggacgacaccgaatcttctcacgctgctacctctaacgtt480

tctgaagacgttcgtgacaacgtttctgttgactacaaacagacccagctgtgcatcctg540

ggttgcgctccggctatcggtgaacactgggctaaaggtaccgcttgcaaatctcgtccg600

ctgtctcagggtgactgcccgccgctggaactgaaaaacaccgttctggaagacggtgac660

atggttgacaccggttacggtgctatggacttctctaccctgcaggacaccaaatgcgaa720

gttccgctggacatctgccagtctatctgcaaatacccggactacctgcagatgtctgct780

gacccgtacggtgactctatgttcttctgcctgcgtcgtgaacagctgttcgctcgtcac840

ttctggaaccgtgctggtaccatgggtgacaccgttccgcagtctctgtacatcaaaggt900

accggtatgcgtgcttctccgggttcttgcgtttactctccgtctccgtctggttctatc960

gttacctctgactctcagctgttcaacaaaccgtactggctgcacaaagctcagggtcac1020

aacaacggtgtttgctggcacaaccagctgttcgttaccgttgttgacaccacccgttct1080

accaacctgaccatctgcgcttctacccagtctccggttccgggtcagtacgacgctacc1140

aaattcaaacagtactctcgtcacgttgaagaatacgacctgcagttcatcttccagctg1200

tgcaccatcaccctgaccgctgacgttatgtcttacatccactctatgaactcttctatc1260

ctggaagactggaacttcggtgttccgccgccgccgaccacctctctggttgacacctac1320

cgtttcgttcagtctgttgctatcacctgccagaaagacgctgctccggctgaaaacaaa1380

gacccgtacgacaaactgaaattctggaacgttgacctgaaagaaaaattctctctggac1440

ctggaccagtacccgctgggtcgtaaattcctggttcaggctggtctgcgtcgtaaaccg1500

accatcggtccgcgtaaacgttctgctccgtctgctaccacctcttctaaaccggctaaa1560

cgtgttcgtgttcgtgctcgtaaa1584

<210>7

<211>1875

<212>DNA

<213> artificial sequence

<400>7

atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat60

atgtctgaccaggaagctaaaccgtctaccgaagacctgggtgacaaaaaagaaggtgaa120

tacatcaaactgaaagttatcggtcaggactcttctgaaatccacttcaaagttaaaatg180

accacccacctgaaaaaactgaaagaatcttactgccagcgtcagggtgttccgatgaac240

tctctgcgtttcctgttcgaaggtcagcgtatcgctgacaaccacaccccgaaagaactg300

ggtatggaagaagaagacgttatcgaagtttaccaggaacagaccggtggatccatggct360

ctgtggcgtccgtctgacaacaccgtttacctgccgccgccgtctgttgctcgtgttgtt420

aacaccgacgactacgttacccgtacctctatcttctaccacgctggttcttctcgtctg480

ctgaccgttggtaacccgtacttccgtgttccggctggtggtggtaacaaacaggacatc540

ccgaaagtttctgcttaccagtaccgtgttttccgtgttcagctgccggacccgaacaaa600

ttcggtctgccggacaactctatctacaacccggaaacccagcgtctggtttgggcttgc660

gctggtgttgaaatcggtcgtggtcagccgctgggtgttggtctgtctggtcacccgttc720

tacaacaaactggacgacaccgaatcttctcacgctgctacctctaacgtttctgaagac780

gttcgtgacaacgtttctgttgactacaaacagacccagctgtgcatcctgggttgcgct840

ccggctatcggtgaacactgggctaaaggtaccgcttgcaaatctcgtccgctgtctcag900

ggtgactgcccgccgctggaactgaaaaacaccgttctggaagacggtgacatggttgac960

accggttacggtgctatggacttctctaccctgcaggacaccaaatgcgaagttccgctg1020

gacatctgccagtctatctgcaaatacccggactacctgcagatgtctgctgacccgtac1080

ggtgactctatgttcttctgcctgcgtcgtgaacagctgttcgctcgtcacttctggaac1140

cgtgctggtaccatgggtgacaccgttccgcagtctctgtacatcaaaggtaccggtatg1200

cgtgcttctccgggttcttgcgtttactctccgtctccgtctggttctatcgttacctct1260

gactctcagctgttcaacaaaccgtactggctgcacaaagctcagggtcacaacaacggt1320

gtttgctggcacaaccagctgttcgttaccgttgttgacaccacccgttctaccaacctg1380

accatctgcgcttctacccagtctccggttccgggtcagtacgacgctaccaaattcaaa1440

cagtactctcgtcacgttgaagaatacgacctgcagttcatcttccagctgtgcaccatc1500

accctgaccgctgacgttatgtcttacatccactctatgaactcttctatcctggaagac1560

tggaacttcggtgttccgccgccgccgaccacctctctggttgacacctaccgtttcgtt1620

cagtctgttgctatcacctgccagaaagacgctgctccggctgaaaacaaagacccgtac1680

gacaaactgaaattctggaacgttgacctgaaagaaaaattctctctggacctggaccag1740

tacccgctgggtcgtaaattcctggttcaggctggtctgcgtcgtaaaccgaccatcggt1800

ccgcgtaaacgttctgctccgtctgctaccacctcttctaaaccggctaaacgtgttcgt1860

gttcgtgctcgtaaa1875

<210>8

<211>738

<212>PRT

<213> artificial sequence

<400>8

MetSerProIleLeuGlyTyrTrpLysIleLysGlyLeuValGlnPro

151015

ThrArgLeuLeuLeuGluTyrLeuGluGluLysTyrGluGluHisLeu

202530

TyrGluArgAspGluGlyAspLysTrpArgAsnLysLysPheGluLeu

354045

GlyLeuGluPheProAsnLeuProTyrTyrIleAspGlyAspValLys

505560

LeuThrGlnSerMetAlaIleIleArgTyrIleAlaAspLysHisAsn

65707580

MetLeuGlyGlyCysProLysGluArgAlaGluIleSerMetLeuGlu

859095

GlyAlaValLeuAspIleArgTyrGlyValSerArgIleAlaTyrSer

100105110

LysAspPheGluThrLeuLysValAspPheLeuSerLysLeuProGlu

115120125

MetLeuLysMetPheGluAspArgLeuCysHisLysThrTyrLeuAsn

130135140

GlyAspHisValThrHisProAspPheMetLeuTyrAspAlaLeuAsp

145150155160

ValValLeuTyrMetAspProMetCysLeuAspAlaPheProLysLeu

165170175

ValCysPheLysLysArgIleGluAlaIleProGlnIleAspLysTyr

180185190

LeuLysSerSerLysTyrIleAlaTrpProLeuGlnGlyTrpGlnAla

195200205

ThrPheGlyGlyGlyAspHisProProLysSerAspLeuGluValLeu

210215220

PheGlnGlyProLeuGlySerMetAlaLeuTrpArgProSerAspAsn

225230235240

ThrValTyrLeuProProProSerValAlaArgValValAsnThrAsp

245250255

AspTyrValThrArgThrSerIlePheTyrHisAlaGlySerSerArg

260265270

LeuLeuThrValGlyAsnProTyrPheArgValProAlaGlyGlyGly

275280285

AsnLysGlnAspIleProLysValSerAlaTyrGlnTyrArgValPhe

290295300

ArgValGlnLeuProAspProAsnLysPheGlyLeuProAspAsnSer

305310315320

IleTyrAsnProGluThrGlnArgLeuValTrpAlaCysAlaGlyVal

325330335

GluIleGlyArgGlyGlnProLeuGlyValGlyLeuSerGlyHisPro

340345350

PheTyrAsnLysLeuAspAspThrGluSerSerHisAlaAlaThrSer

355360365

AsnValSerGluAspValArgAspAsnValSerValAspTyrLysGln

370375380

ThrGlnLeuCysIleLeuGlyCysAlaProAlaIleGlyGluHisTrp

385390395400

AlaLysGlyThrAlaCysLysSerArgProLeuSerGlnGlyAspCys

405410415

ProProLeuGluLeuLysAsnThrValLeuGluAspGlyAspMetVal

420425430

AspThrGlyTyrGlyAlaMetAspPheSerThrLeuGlnAspThrLys

435440445

CysGluValProLeuAspIleCysGlnSerIleCysLysTyrProAsp

450455460

TyrLeuGlnMetSerAlaAspProTyrGlyAspSerMetPhePheCys

465470475480

LeuArgArgGluGlnLeuPheAlaArgHisPheTrpAsnArgAlaGly

485490495

ThrMetGlyAspThrValProGlnSerLeuTyrIleLysGlyThrGly

500505510

MetArgAlaSerProGlySerCysValTyrSerProSerProSerGly

515520525

SerIleValThrSerAspSerGlnLeuPheAsnLysProTyrTrpLeu

530535540

HisLysAlaGlnGlyHisAsnAsnGlyValCysTrpHisAsnGlnLeu

545550555560

PheValThrValValAspThrThrArgSerThrAsnLeuThrIleCys

565570575

AlaSerThrGlnSerProValProGlyGlnTyrAspAlaThrLysPhe

580585590

LysGlnTyrSerArgHisValGluGluTyrAspLeuGlnPheIlePhe

595600605

GlnLeuCysThrIleThrLeuThrAlaAspValMetSerTyrIleHis

610615620

SerMetAsnSerSerIleLeuGluAspTrpAsnPheGlyValProPro

625630635640

ProProThrThrSerLeuValAspThrTyrArgPheValGlnSerVal

645650655

AlaIleThrCysGlnLysAspAlaAlaProAlaGluAsnLysAspPro

660665670

TyrAspLysLeuLysPheTrpAsnValAspLeuLysGluLysPheSer

675680685

LeuAspLeuAspGlnTyrProLeuGlyArgLysPheLeuValGlnAla

690695700

GlyLeuArgArgLysProThrIleGlyProArgLysArgSerAlaPro

705710715720

SerAlaThrThrSerSerLysProAlaLysArgValArgValArgAla

725730735

ArgLys

<210>9

<211>832

<212>PRT

<213> artificial sequence

<400>9

MetSerProIleLeuGlyTyrTrpLysIleLysGlyLeuValGlnPro

151015

ThrArgLeuLeuLeuGluTyrLeuGluGluLysTyrGluGluHisLeu

202530

TyrGluArgAspGluGlyAspLysTrpArgAsnLysLysPheGluLeu

354045

GlyLeuGluPheProAsnLeuProTyrTyrIleAspGlyAspValLys

505560

LeuThrGlnSerMetAlaIleIleArgTyrIleAlaAspLysHisAsn

65707580

MetLeuGlyGlyCysProLysGluArgAlaGluIleSerMetLeuGlu

859095

GlyAlaValLeuAspIleArgTyrGlyValSerArgIleAlaTyrSer

100105110

LysAspPheGluThrLeuLysValAspPheLeuSerLysLeuProGlu

115120125

MetLeuLysMetPheGluAspArgLeuCysHisLysThrTyrLeuAsn

130135140

GlyAspHisValThrHisProAspPheMetLeuTyrAspAlaLeuAsp

145150155160

ValValLeuTyrMetAspProMetCysLeuAspAlaPheProLysLeu

165170175

ValCysPheLysLysArgIleGluAlaIleProGlnIleAspLysTyr

180185190

LeuLysSerSerLysTyrIleAlaTrpProLeuGlnGlyTrpGlnAla

195200205

ThrPheGlyGlyGlyAspHisProProLysSerAspLeuGluValLeu

210215220

PheGlnGlyProSerAspGlnGluAlaLysProSerThrGluAspLeu

225230235240

GlyAspLysLysGluGlyGluTyrIleLysLeuLysValIleGlyGln

245250255

AspSerSerGluIleHisPheLysValLysMetThrThrHisLeuLys

260265270

LysLeuLysGluSerTyrCysGlnArgGlnGlyValProMetAsnSer

275280285

LeuArgPheLeuPheGluGlyGlnArgIleAlaAspAsnHisThrPro

290295300

LysGluLeuGlyMetGluGluGluAspValIleGluValTyrGlnGlu

305310315320

GlnThrGlyGlySerMetAlaLeuTrpArgProSerAspAsnThrVal

325330335

TyrLeuProProProSerValAlaArgValValAsnThrAspAspTyr

340345350

ValThrArgThrSerIlePheTyrHisAlaGlySerSerArgLeuLeu

355360365

ThrValGlyAsnProTyrPheArgValProAlaGlyGlyGlyAsnLys

370375380

GlnAspIleProLysValSerAlaTyrGlnTyrArgValPheArgVal

385390395400

GlnLeuProAspProAsnLysPheGlyLeuProAspAsnSerIleTyr

405410415

AsnProGluThrGlnArgLeuValTrpAlaCysAlaGlyValGluIle

420425430

GlyArgGlyGlnProLeuGlyValGlyLeuSerGlyHisProPheTyr

435440445

AsnLysLeuAspAspThrGluSerSerHisAlaAlaThrSerAsnVal

450455460

SerGluAspValArgAspAsnValSerValAspTyrLysGlnThrGln

465470475480

LeuCysIleLeuGlyCysAlaProAlaIleGlyGluHisTrpAlaLys

485490495

GlyThrAlaCysLysSerArgProLeuSerGlnGlyAspCysProPro

500505510

LeuGluLeuLysAsnThrValLeuGluAspGlyAspMetValAspThr

515520525

GlyTyrGlyAlaMetAspPheSerThrLeuGlnAspThrLysCysGlu

530535540

ValProLeuAspIleCysGlnSerIleCysLysTyrProAspTyrLeu

545550555560

GlnMetSerAlaAspProTyrGlyAspSerMetPhePheCysLeuArg

565570575

ArgGluGlnLeuPheAlaArgHisPheTrpAsnArgAlaGlyThrMet

580585590

GlyAspThrValProGlnSerLeuTyrIleLysGlyThrGlyMetArg

595600605

AlaSerProGlySerCysValTyrSerProSerProSerGlySerIle

610615620

ValThrSerAspSerGlnLeuPheAsnLysProTyrTrpLeuHisLys

625630635640

AlaGlnGlyHisAsnAsnGlyValCysTrpHisAsnGlnLeuPheVal

645650655

ThrValValAspThrThrArgSerThrAsnLeuThrIleCysAlaSer

660665670

ThrGlnSerProValProGlyGlnTyrAspAlaThrLysPheLysGln

675680685

TyrSerArgHisValGluGluTyrAspLeuGlnPheIlePheGlnLeu

690695700

CysThrIleThrLeuThrAlaAspValMetSerTyrIleHisSerMet

705710715720

AsnSerSerIleLeuGluAspTrpAsnPheGlyValProProProPro

725730735

ThrThrSerLeuValAspThrTyrArgPheValGlnSerValAlaIle

740745750

ThrCysGlnLysAspAlaAlaProAlaGluAsnLysAspProTyrAsp

755760765

LysLeuLysPheTrpAsnValAspLeuLysGluLysPheSerLeuAsp

770775780

LeuAspGlnTyrProLeuGlyArgLysPheLeuValGlnAlaGlyLeu

785790795800

ArgArgLysProThrIleGlyProArgLysArgSerAlaProSerAla

805810815

ThrThrSerSerLysProAlaLysArgValArgValArgAlaArgLys

820825830

<210>10

<211>898

<212>PRT

<213> artificial sequence

<400>10

MetLysIleGluGluGlyLysLeuValIleTrpIleAsnGlyAspLys

151015

GlyTyrAsnGlyLeuAlaGluValGlyLysLysPheGluLysAspThr

202530

GlyIleLysValThrValGluHisProAspLysLeuGluGluLysPhe

354045

ProGlnValAlaAlaThrGlyAspGlyProAspIleIlePheTrpAla

505560

HisAspArgPheGlyGlyTyrAlaGlnSerGlyLeuLeuAlaGluIle

65707580

ThrProAspLysAlaPheGlnAspLysLeuTyrProPheThrTrpAsp

859095

AlaValArgTyrAsnGlyLysLeuIleAlaTyrProIleAlaValGlu

100105110

AlaLeuSerLeuIleTyrAsnLysAspLeuLeuProAsnProProLys

115120125

ThrTrpGluGluIleProAlaLeuAspLysGluLeuLysAlaLysGly

130135140

LysSerAlaLeuMetPheAsnLeuGlnGluProTyrPheThrTrpPro

145150155160

LeuIleAlaAlaAspGlyGlyTyrAlaPheLysTyrGluAsnGlyLys

165170175

TyrAspIleLysAspValGlyValAspAsnAlaGlyAlaLysAlaGly

180185190

LeuThrPheLeuValAspLeuIleLysAsnLysHisMetAsnAlaAsp

195200205

ThrAspTyrSerIleAlaGluAlaAlaPheAsnLysGlyGluThrAla

210215220

MetThrIleAsnGlyProTrpAlaTrpSerAsnIleAspThrSerLys

225230235240

ValAsnTyrGlyValThrValLeuProThrPheLysGlyGlnProSer

245250255

LysProPheValGlyValLeuSerAlaGlyIleAsnAlaAlaSerPro

260265270

AsnLysGluLeuAlaLysGluPheLeuGluAsnTyrLeuLeuThrAsp

275280285

GluGlyLeuGluAlaValAsnLysAspLysProLeuGlyAlaValAla

290295300

LeuLysSerTyrGluGluGluLeuAlaLysAspProArgIleAlaAla

305310315320

ThrMetGluAsnAlaGlnLysGlyGluIleMetProAsnIleProGln

325330335

MetSerAlaPheTrpTyrAlaValArgThrAlaValIleAsnAlaAla

340345350

SerGlyArgGlnThrValAspGluAlaLeuLysAspAlaGlnThrAsn

355360365

SerSerSerAsnAsnAsnAsnAsnAsnAsnAsnAsnAsnLeuGlyIle

370375380

GluGlyArgIleSerGluPheMetAlaLeuTrpArgProSerAspAsn

385390395400

ThrValTyrLeuProProProSerValAlaArgValValAsnThrAsp

405410415

AspTyrValThrArgThrSerIlePheTyrHisAlaGlySerSerArg

420425430

LeuLeuThrValGlyAsnProTyrPheArgValProAlaGlyGlyGly

435440445

AsnLysGlnAspIleProLysValSerAlaTyrGlnTyrArgValPhe

450455460

ArgValGlnLeuProAspProAsnLysPheGlyLeuProAspAsnSer

465470475480

IleTyrAsnProGluThrGlnArgLeuValTrpAlaCysAlaGlyVal

485490495

GluIleGlyArgGlyGlnProLeuGlyValGlyLeuSerGlyHisPro

500505510

PheTyrAsnLysLeuAspAspThrGluSerSerHisAlaAlaThrSer

515520525

AsnValSerGluAspValArgAspAsnValSerValAspTyrLysGln

530535540

ThrGlnLeuCysIleLeuGlyCysAlaProAlaIleGlyGluHisTrp

545550555560

AlaLysGlyThrAlaCysLysSerArgProLeuSerGlnGlyAspCys

565570575

ProProLeuGluLeuLysAsnThrValLeuGluAspGlyAspMetVal

580585590

AspThrGlyTyrGlyAlaMetAspPheSerThrLeuGlnAspThrLys

595600605

CysGluValProLeuAspIleCysGlnSerIleCysLysTyrProAsp

610615620

TyrLeuGlnMetSerAlaAspProTyrGlyAspSerMetPhePheCys

625630635640

LeuArgArgGluGlnLeuPheAlaArgHisPheTrpAsnArgAlaGly

645650655

ThrMetGlyAspThrValProGlnSerLeuTyrIleLysGlyThrGly

660665670

MetArgAlaSerProGlySerCysValTyrSerProSerProSerGly

675680685

SerIleValThrSerAspSerGlnLeuPheAsnLysProTyrTrpLeu

690695700

HisLysAlaGlnGlyHisAsnAsnGlyValCysTrpHisAsnGlnLeu

705710715720

PheValThrValValAspThrThrArgSerThrAsnLeuThrIleCys

725730735

AlaSerThrGlnSerProValProGlyGlnTyrAspAlaThrLysPhe

740745750

LysGlnTyrSerArgHisValGluGluTyrAspLeuGlnPheIlePhe

755760765

GlnLeuCysThrIleThrLeuThrAlaAspValMetSerTyrIleHis

770775780

SerMetAsnSerSerIleLeuGluAspTrpAsnPheGlyValProPro

785790795800

ProProThrThrSerLeuValAspThrTyrArgPheValGlnSerVal

805810815

AlaIleThrCysGlnLysAspAlaAlaProAlaGluAsnLysAspPro

820825830

TyrAspLysLeuLysPheTrpAsnValAspLeuLysGluLysPheSer

835840845

LeuAspLeuAspGlnTyrProLeuGlyArgLysPheLeuValGlnAla

850855860

GlyLeuArgArgLysProThrIleGlyProArgLysArgSerAlaPro

865870875880

SerAlaThrThrSerSerLysProAlaLysArgValArgValArgAla

885890895

ArgLys

<210>11

<211>2100

<212>DNA

<213> artificial sequence

<400>11

atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60

ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120

tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180

ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240

atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300

gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360

gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420

acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480

gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540

aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600

tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660

ctggaagttctgttccaggggccctctgacaacaccgtttacctgccgccgccgtctgtt720

gctcgtgttgttaacaccgacgactacgttacccgtacctctatcttctaccacgctggt780

tcttctcgtctgctgaccgttggtaacccgtacttccgtgttccggctggtggtggtaac840

aaacaggacatcccgaaagtttctgcttaccagtaccgtgttttccgtgttcagctgccg900

gacccgaacaaattcggtctgccggacaactctatctacaacccggaaacccagcgtctg960

gtttgggcttgcgctggtgttgaaatcggtcgtggtcagccgctgggtgttggtctgtct1020

ggtcacccgttctacaacaaactggacgacaccgaatcttctcacgctgctacctctaac1080

gtttctgaagacgttcgtgacaacgtttctgttgactacaaacagacccagctgtgcatc1140

ctgggttgcgctccggctatcggtgaacactgggctaaaggtaccgcttgcaaatctcgt1200

ccgctgtctcagggtgactgcccgccgctggaactgaaaaacaccgttctggaagacggt1260

gacatggttgacaccggttacggtgctatggacttctctaccctgcaggacaccaaatgc1320

gaagttccgctggacatctgccagtctatctgcaaatacccggactacctgcagatgtct1380

gctgacccgtacggtgactctatgttcttctgcctgcgtcgtgaacagctgttcgctcgt1440

cacttctggaaccgtgctggtaccatgggtgacaccgttccgcagtctctgtacatcaaa1500

ggtaccggtatgcgtgcttctccgggttcttgcgtttactctccgtctccgtctggttct1560

atcgttacctctgactctcagctgttcaacaaaccgtactggctgcacaaagctcagggt1620

cacaacaacggtgtttgctggcacaaccagctgttcgttaccgttgttgacaccacccgt1680

tctaccaacctgaccatctgcgcttctacccagtctccggttccgggtcagtacgacgct1740

accaaattcaaacagtactctcgtcacgttgaagaatacgacctgcagttcatcttccag1800

ctgtgcaccatcaccctgaccgctgacgttatgtcttacatccactctatgaactcttct1860

atcctggaagactggaacttcggtgttccgccgccgccgaccacctctctggttgacacc1920

taccgtttcgttcagtctgttgctatcacctgccagaaagacgctgctccggctgaaaac1980

aaagacccgtacgacaaactgaaattctggaacgttgacctgaaagaaaaattctctctg2040

gacctggaccagtacccgctgggtcgtaaattcctggttcaggctggtctgcgtcgttag2100

<210>12

<211>2478

<212>DNA

<213> artificial sequence

<400>12

atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60

ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120

tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180

ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240

atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300

gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360

gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420

acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480

gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540

aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600

tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660

ctggaagttctgttccaggggccctctgaccaggaagctaaaccgtctaccgaagacctg720

ggtgacaaaaaagaaggtgaatacatcaaactgaaagttatcggtcaggactcttctgaa780

atccacttcaaagttaaaatgaccacccacctgaaaaaactgaaagaatcttactgccag840

cgtcagggtgttccgatgaactctctgcgtttcctgttcgaaggtcagcgtatcgctgac900

aaccacaccccgaaagaactgggtatggaagaagaagacgttatcgaagtttaccaggaa960

cagaccggtggatcctctgacaacaccgtttacctgccgccgccgtctgttgctcgtgtt1020

gttaacaccgacgactacgttacccgtacctctatcttctaccacgctggttcttctcgt1080

ctgctgaccgttggtaacccgtacttccgtgttccggctggtggtggtaacaaacaggac1140

atcccgaaagtttctgcttaccagtaccgtgttttccgtgttcagctgccggacccgaac1200

aaattcggtctgccggacaactctatctacaacccggaaacccagcgtctggtttgggct1260

tgcgctggtgttgaaatcggtcgtggtcagccgctgggtgttggtctgtctggtcacccg1320

ttctacaacaaactggacgacaccgaatcttctcacgctgctacctctaacgtttctgaa1380

gacgttcgtgacaacgtttctgttgactacaaacagacccagctgtgcatcctgggttgc1440

gctccggctatcggtgaacactgggctaaaggtaccgcttgcaaatctcgtccgctgtct1500

cagggtgactgcccgccgctggaactgaaaaacaccgttctggaagacggtgacatggtt1560

gacaccggttacggtgctatggacttctctaccctgcaggacaccaaatgcgaagttccg1620

ctggacatctgccagtctatctgcaaatacccggactacctgcagatgtctgctgacccg1680

tacggtgactctatgttcttctgcctgcgtcgtgaacagctgttcgctcgtcacttctgg1740

aaccgtgctggtaccatgggtgacaccgttccgcagtctctgtacatcaaaggtaccggt1800

atgcgtgcttctccgggttcttgcgtttactctccgtctccgtctggttctatcgttacc1860

tctgactctcagctgttcaacaaaccgtactggctgcacaaagctcagggtcacaacaac1920

ggtgtttgctggcacaaccagctgttcgttaccgttgttgacaccacccgttctaccaac1980

ctgaccatctgcgcttctacccagtctccggttccgggtcagtacgacgctaccaaattc2040

aaacagtactctcgtcacgttgaagaatacgacctgcagttcatcttccagctgtgcacc2100

atcaccctgaccgctgacgttatgtcttacatccactctatgaactcttctatcctggaa2160

gactggaacttcggtgttccgccgccgccgaccacctctctggttgacacctaccgtttc2220

gttcagtctgttgctatcacctgccagaaagacgctgctccggctgaaaacaaagacccg2280

tacgacaaactgaaattctggaacgttgacctgaaagaaaaattctctctggacctggac2340

cagtacccgctgggtcgtaaattcctggttcaggctggtctgcgtcgtaaaccgaccatc2400

ggtccgcgtaaacgttctgctccgtctgctaccacctcttctaaaccggctaaacgtgtt2460

cgtgttcgtgctcgtaaa2478

<210>13

<211>2649

<212>DNA

<213> artificial sequence

<400>13

atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt60

ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat120

ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt180

atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc240

accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac300

aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa360

gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg420

aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg480

ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa540

gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt600

aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa660

ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa720

gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt780

ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc840

ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg900

ggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgcc960

actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc1020

tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa1080

gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac1140

aacctcgggatcgagggaaggatttcagaattcatggctctgtggcgtccgtctgacaac1200

accgtttacctgccgccgccgtctgttgctcgtgttgttaacaccgacgactacgttacc1260

cgtacctctatcttctaccacgctggttcttctcgtctgctgaccgttggtaacccgtac1320

ttccgtgttccggctggtggtggtaacaaacaggacatcccgaaagtttctgcttaccag1380

taccgtgttttccgtgttcagctgccggacccgaacaaattcggtctgccggacaactct1440

atctacaacccggaaacccagcgtctggtttgggcttgcgctggtgttgaaatcggtcgt1500

ggtcagccgctgggtgttggtctgtctggtcacccgttctacaacaaactggacgacacc1560

gaatcttctcacgctgctacctctaacgtttctgaagacgttcgtgacaacgtttctgtt1620

gactacaaacagacccagctgtgcatcctgggttgcgctccggctatcggtgaacactgg1680

gctaaaggtaccgcttgcaaatctcgtccgctgtctcagggtgactgcccgccgctggaa1740

ctgaaaaacaccgttctggaagacggtgacatggttgacaccggttacggtgctatggac1800

ttctctaccctgcaggacaccaaatgcgaagttccgctggacatctgccagtctatctgc1860

aaatacccggactacctgcagatgtctgctgacccgtacggtgactctatgttcttctgc1920

ctgcgtcgtgaacagctgttcgctcgtcacttctggaaccgtgctggtaccatgggtgac1980

accgttccgcagtctctgtacatcaaaggtaccggtatgcgtgcttctccgggttcttgc2040

gtttactctccgtctccgtctggttctatcgttacctctgactctcagctgttcaacaaa2100

ccgtactggctgcacaaagctcagggtcacaacaacggtgtttgctggcacaaccagctg2160

ttcgttaccgttgttgacaccacccgttctaccaacctgaccatctgcgcttctacccag2220

tctccggttccgggtcagtacgacgctaccaaattcaaacagtactctcgtcacgttgaa2280

gaatacgacctgcagttcatcttccagctgtgcaccatcaccctgaccgctgacgttatg2340

tcttacatccactctatgaactcttctatcctggaagactggaacttcggtgttccgccg2400

ccgccgaccacctctctggttgacacctaccgtttcgttcagtctgttgctatcacctgc2460

cagaaagacgctgctccggctgaaaacaaagacccgtacgacaaactgaaattctggaac2520

gttgacctgaaagaaaaattctctctggacctggaccagtacccgctgggtcgtaaattc2580

ctggttcaggctggtctgcgtcgtaaaccgaccatcggtccgcgtaaacgttctgctccg2640

tctgctacc2649

Claims (21)

1., through a gene of the encoding human papilloma virus HPV18L1 of intestinal bacteria preferred codons optimization, this gene is the nucleotide sequence shown in SEQNO.2.

2. a coli expression carrier, is characterized in that this carrier comprises the sequence with gene described in claim 1.

3. coli expression carrier as claimed in claim 2, is characterized in that this carrier is pGEX-6p-1, pGEX-4T-2, pMAL or pET28a.

4. an engineering bacteria cell, this cell comprises gene according to claim 1, or the expression vector described in claim 2,3.

5. the fusion rotein of a Tag-HPV18L1, it is characterized in that this albumen comprises the gene of encoding human papilloma virus HPV18L1, preferably through the gene of the encoding human papilloma virus HPV18L1 of intestinal bacteria preferred codons optimization, more preferably genes encoding as claimed in claim 1; Label Tag is GST.Tag, MBP.Tag or GST-SUMO.Tag.

6. fusion rotein as claimed in claim 5, is characterized in that L1 protein is that full length protein or C hold no more than 30 amino acid of brachymemma and/or N to hold no more than 10 the amino acid whose L1 protein of brachymemma.

7. fusion rotein as claimed in claim 5, is characterized in that its nucleotides sequence is classified as SEQNO.3, SEQNO.4, SEQNO.5, SEQNO.11, SEQNO.12 or SEQNO.13.

8. fusion rotein as claimed in claim 5, is characterized in that its aminoacid sequence is SEQNO.8, SEQNO.9 or SEQNO.10.

9. a HPV18L1 pentamer protein, is characterized in that this pentamer protein is obtained after purifying by the fused protein as described in claim 5,6,7 or 8, pentamer albumen median size 10 ~ 15nmPdI<0.1.

10. a VLP of HPV18L1, is characterized in that this VLP is formed by pentamer protein assembly according to claim 9, median size 45 ~ 65nmPdI<0.1.

11. 1 kinds of HPVL1 protein vaccine compositions, is characterized in that this vaccine composition comprises HPVL1 pentamer protein according to claim 9 and medicinal adjuvant.

12. a HPVL1 protein vaccine composition, it is characterized in that this vaccine composition comprises HPVL1VLP according to claim 10 and medicinal adjuvant.

The preparation method of 13. fusion roteins as described in claim 5,6,7 or 8, is characterized in that the method comprises the steps:

By replacing the codon of HPV18L1 gene order with the codon of intestinal bacteria preference, obtain the gene of codon optimized HPV18L1;

Build the coli expression carrier of HPV18L1 gene;

Build the escherichia coli expression engineering strain of Tag-HPV18L1;

Abduction delivering purifying obtains fusion rotein Tag-HPV18L1.

14. method as claimed in claim 13, wherein said prokaryotic host cell is GI698, ER2566, BL21 (DE3), XA90, B834 (DE3) or BLR (DE3), preferred BL21 (DE3).

The preparation method of 15. HPV18L1 pentamer protein as claimed in claim 9, is characterized in that the method comprises the steps:

With affinity chromatography method absorption fusion rotein Tag-HPV18L1;

Add proteolytic enzyme excision Tag label, obtain HPV18L1 pentamer protein;

Purifying HPVL1 pentamer protein, the L1 pentamer protein of purity >98%, median size 10 ~ 15nmPdI<0.1.

The preparation method of 16. HPV18L1 pentamer protein as claimed in claim 15, is characterized in that described proteolytic enzyme is the site-specific proteolytic enzyme of excision Tag label: restructuring HRV 3CP, zymoplasm, SUMO proteolytic enzyme, SENP1 or TEV protease.

The preparation method of 17. HPV18L1VLP as claimed in claim 10, is characterized in that the method comprises the steps:

The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is mixed with assembling damping fluid, final acquisition pH value is 5.0 ~ 5.9, salt concn is 500 ~ 2000mM, the HPV18L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.

18. a preparation method of HPV18L1-VLP as claimed in claim 10 is assembled in cryogenic freezing process, it is characterized in that the method comprises the steps:

The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is placed in pH value is 5.5 ~ 8.0 salt concn is damping fluid under 150 ~ 1000mM condition, completely freezing under-20 ~-80 DEG C of conditions, place room temperature again to melt to protein stoste, obtain the HPV18L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.

19. the application of HPV18L1 pentamer protein as claimed in claim 9 in the medicine of preparation prevention HPV18 infection.

20. the application of HPV18L1VLP protein as claimed in claim 10 in the medicine of preparation prevention HPV18 infection.

Application in the medicine that 21. vaccine compositions as described in claim 11 or 12 infect at preparation prevention HPV18.